New Medical Technique Can Actually Predict Complications after Surgery for Larynx Cancer
9The study involved 52 patients
52 patients with advanced oropharyngeal cancer enrolled for the study where 22 had developed a recurrence of cancer and 30 who had not. Both groups had similarities of age, classification of cancer and status of smoking. All had tumors linked to HPV. In most cases of recurrence, it was found that cancer usually recurred after 13 months after treatment ended. A blood test was carried out in the beginning of treatment and every three months thereafter.
10A decline of antibodies
After three months of treatment all patients showed decline of antibodies and there was no difference in E6 and E7. Professor Spector said “Most patients recur within the first two years, so the window to catch it is two years after treatment. Everyone’s level goes down over time, but some start to go up a little — and those is the ones we have to focus on.”
11Certain biomarkers measured differently
After studying E6 and E 7 antibody levels, researchers found that in those patients where cancer recurred, E7 levels did not reduce as quickly as in those patients with any recurrence. They also detected the point from when the recurrence was observed. Professor Spector remarked “If we can monitor someone through blood markers, then instead of a patient coming for a clinic visit every two to three months, they could get blood drawn near home. If there’s evidence of high E7, we can tell the patient to come in for more evaluation,”
12The antibodies is the key
The research feels that the main key is the ratio of antibodies in E7 where every patient may have a different baseline level and that the absolute level was not exactly an indication. Spector said that every patient has different levels but the main question is that when tracked over time then recurrence is denoted with arise in levels of antibodies.
13Phase 2 underway
If recurrence of the cancer is found out early then surgery of the throat and neck can eliminate the disease till cure. If the cancer has spread to the lungs area, early target therapies will provide better results. Moreover the E6 and E7 antibodies test which is a standard one can be carried out by any cancer facility and would be inexpensive to perform. A phase 2 trial is now underway by the University of Michigan to see if E7 could now be used as a biomarker for recurrence.